Frontiers in Immunology (Apr 2022)

Peptides-Coated Oncolytic Vaccines for Cancer Personalized Medicine

  • Sara Feola,
  • Sara Feola,
  • Sara Feola,
  • Sara Feola,
  • Salvatore Russo,
  • Salvatore Russo,
  • Salvatore Russo,
  • Salvatore Russo,
  • Beatriz Martins,
  • Beatriz Martins,
  • Beatriz Martins,
  • Beatriz Martins,
  • Alessandra Lopes,
  • Gaëlle Vandermeulen,
  • Vinciane Fluhler,
  • Vinciane Fluhler,
  • Vinciane Fluhler,
  • Vinciane Fluhler,
  • Camilla De Giorgi,
  • Camilla De Giorgi,
  • Camilla De Giorgi,
  • Camilla De Giorgi,
  • Manlio Fusciello,
  • Manlio Fusciello,
  • Manlio Fusciello,
  • Manlio Fusciello,
  • Sari Pesonen,
  • Erkko Ylösmäki,
  • Erkko Ylösmäki,
  • Erkko Ylösmäki,
  • Erkko Ylösmäki,
  • Gabriella Antignani,
  • Gabriella Antignani,
  • Gabriella Antignani,
  • Gabriella Antignani,
  • Jacopo Chiaro,
  • Jacopo Chiaro,
  • Jacopo Chiaro,
  • Jacopo Chiaro,
  • Firas Hamdan,
  • Firas Hamdan,
  • Firas Hamdan,
  • Firas Hamdan,
  • Michaela Feodoroff,
  • Michaela Feodoroff,
  • Michaela Feodoroff,
  • Michaela Feodoroff,
  • Mikaela Grönholm,
  • Mikaela Grönholm,
  • Mikaela Grönholm,
  • Mikaela Grönholm,
  • Vincenzo Cerullo,
  • Vincenzo Cerullo,
  • Vincenzo Cerullo,
  • Vincenzo Cerullo,
  • Vincenzo Cerullo

DOI
https://doi.org/10.3389/fimmu.2022.826164
Journal volume & issue
Vol. 13

Abstract

Read online

Oncolytic Viruses (OVs) work through two main mechanisms of action: the direct lysis of the virus-infected cancer cells and the release of tumor antigens as a result of the viral burst. In this sc.enario, the OVs act as in situ cancer vaccines, since the immunogenicity of the virus is combined with tumor antigens, that direct the specificity of the anti-tumor adaptive immune response. However, this mechanism in some cases fails in eliciting a strong specific T cell response. One way to overcome this problem and enhance the priming efficiency is the production of genetically modified oncolytic viruses encoding one or more tumor antigens. To avoid the long and expensive process related to the engineering of the OVs, we have exploited an approach based on coating OVs (adenovirus and vaccinia virus) with tumor antigens. In this work, oncolytic viruses encoding tumor antigens and tumor antigen decorated adenoviral platform (PeptiCRAd) have been used as cancer vaccines and evaluated both for their prophylactic and therapeutic efficacy. We have first tested the oncolytic vaccines by exploiting the OVA model, moving then to TRP2, a more clinically relevant tumor antigen. Finally, both approaches have been investigated in tumor neo-antigens settings. Interestingly, both genetically modified oncolytic adenovirus and PeptiCRAd elicited T cells-specific anti-tumor responses. However, in vitro cross-representation experiments, showed an advantage of PeptiCRAd as regards the fast presentation of the model epitope SIINFEKL from OVA in an immunogenic rather than tolerogenic fashion. Here two approaches used as cancer oncolytic vaccines have been explored and characterized for their efficacy. Although the generation of specific anti-tumor T cells was elicited in both approaches, PeptiCRAd retains the advantage of being rapidly adaptable by coating the adenovirus with a different set of tumor antigens, which is crucial in personalized cancer vaccines clinical setting.

Keywords